Dan Gladwell

Chief of HTA Strategy, HEOR

Dan joined the company in 2011, when the company was known as BresMed. Before joining the company, Dan worked in R&D for Takeda Europe, leading the pre-, peri- and post-launch health economics and outcomes research (HEOR) planning for diabetes and obesity compounds. He has led the development of cost-effectiveness models and health technology assessment (HTA) submissions – providing strategic guidance on HEOR and market access. Dan achieved a PhD investigating the dynamic impact of health difficulties in adolescence on the formation of valued abilities and skills. Dan works with the HEOR Board to develop and articulate strategic direction.